ID: ALA159723

Max Phase: Preclinical

Molecular Formula: C44H58N6O14

Molecular Weight: 894.98

Molecule Type: Protein

Associated Items:

Representations

Canonical SMILES:  CC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(C)=O)C(c1ccccc1)c1ccccc1)C(=O)O

Standard InChI:  InChI=1S/C44H58N6O14/c1-3-29(44(63)64)46-41(60)32(23-26-13-7-4-8-14-26)49-39(58)30(19-21-34(52)53)48-43(62)38(37(27-15-9-5-10-16-27)28-17-11-6-12-18-28)50-40(59)31(20-22-35(54)55)47-42(61)33(24-36(56)57)45-25(2)51/h5-6,9-12,15-18,26,29-33,37-38H,3-4,7-8,13-14,19-24H2,1-2H3,(H,45,51)(H,46,60)(H,47,61)(H,48,62)(H,49,58)(H,50,59)(H,52,53)(H,54,55)(H,56,57)(H,63,64)/t29-,30-,31-,32-,33-,38-/m0/s1

Standard InChI Key:  HCCZVIPVSOHWHY-PRSJUXBDSA-N

Associated Targets(non-human)

NS4A Hepatitis C virus serine protease, NS3/NS4A (1215 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
NS3 protease (56 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: ProteinTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 894.98Molecular Weight (Monoisotopic): 894.4011AlogP: 1.42#Rotatable Bonds: 26
Polar Surface Area: 323.80Molecular Species: ACIDHBA: 10HBD: 10
#RO5 Violations: 2HBA (Lipinski): 20HBD (Lipinski): 10#RO5 Violations (Lipinski): 3
CX Acidic pKa: 3.25CX Basic pKa: CX LogP: 1.01CX LogD: -11.84
Aromatic Rings: 2Heavy Atoms: 64QED Weighted: 0.06Np Likeness Score: 0.18

References

1. Narjes F, Koehler KF, Koch U, Gerlach B, Colarusso S, Steinkühler C, Brunetti M, Altamura S, De Francesco R, Matassa VG..  (2002)  A designed P1 cysteine mimetic for covalent and non-covalent inhibitors of HCV NS3 protease.,  12  (4): [PMID:11844705] [10.1016/s0960-894x(01)00842-3]
2. Meanwell NA..  (2011)  Synopsis of some recent tactical application of bioisosteres in drug design.,  54  (8): [PMID:21413808] [10.1021/jm1013693]
3. Meanwell NA..  (2018)  Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design.,  61  (14): [PMID:29400967] [10.1021/acs.jmedchem.7b01788]
4. Mei H, Han J, Klika KD, Izawa K, Sato T, Meanwell NA, Soloshonok VA..  (2020)  Applications of fluorine-containing amino acids for drug design.,  186  [PMID:31740056] [10.1016/j.ejmech.2019.111826]
5. Meanwell NA..  (2016)  2015 Philip S. Portoghese Medicinal Chemistry Lectureship. Curing Hepatitis C Virus Infection with Direct-Acting Antiviral Agents: The Arc of a Medicinal Chemistry Triumph.,  59  (16): [PMID:27501244] [10.1021/acs.jmedchem.6b00915]

Source